Interní Med. 2009; 11(5): 224-227

Advanced forms of insulinotherapy patients with type 2 diabetes mellitus

MUDr. Dagmar Bartášková
Diabetologické centrum FN Motol, Praha

Type 2. diabetes mellitus is connected with growing number late diabetics macrovascular complications as well as with higher expenditures

for the treatment. There are clinical studies, which evaluate influence of tight diabetic control on macrovasular complications

development. The conclusion is new recommendation concerning final level HbA1c and present macrovasular complications. This article

presents new possibilities in insulin treatment type 2. diabetes mellitus relating individual diabetics patient.

Keywords: type 2. diabetes mellitus, macrovascular complications, insulin therapy initiation.

Published: June 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bartášková D. Advanced forms of insulinotherapy patients with type 2 diabetes mellitus. Interní Med. 2009;11(5):224-227.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Perušičová J. Nová doporučení pro léčbu diabetes mellitus 2. typu. Interní Med. 2007; 4: 158-162.
    2. Nathan DM, Buse JB, Davidson MB. Management of hyperglycemia type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care, 2006; 29(8): 1963-1972. Go to original source... Go to PubMed...
    3. UK Prospective Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patiens with type 2 diabetes. Lancet 1998; 352: 837-853. Go to original source...
    4. Holman R, et al. 10-year follow up of intensit glukose kontrol in Type 2 diabetes. N Engl J Med 2008, 359. Go to original source... Go to PubMed...
    5. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensit glukose lowering in type 2 diabetes. N Engl. J Med 2008; 358: 2545-2559. Go to original source... Go to PubMed...
    6. The Action to Control Cardiovascular Risk in Diabetes Study Group: lycemia treatment strategies in the action to control cardiovascular risk in diabetes (ACCORD) trial. Am J Cardiol 2007; 99 (Suppl): 34i-43i.
    7. The Action to Control Cardiovascular Risk in Diabetes Study Group: Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99 (Suppl): 21i-33i.
    8. The ADVANCE ollaboration Group: Intensive blood glukose control and vascular outcomes in patiens with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. Go to original source... Go to PubMed...
    9. Honka M. Inzulin detemir. Remedia 2008, 1: 24-33.
    10. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin - associated weight gain. Diabetes, Obesity and Metabolism 2006, 1-8.
    11. De Vries JH. Refining basal insulin therapy: What have we learned in the age of analogues? Diabetes Metab. Res Rev. 2007; 23: 441-454. Go to original source... Go to PubMed...
    12. Rosenstock J, Davies M. Insulin detemir added to oral antidiabetic drugs in type 2 diabetes provils glycemic kontrol comparable to insulin margine with less weight gain. Diabetes 2006; 55 (Suppl.1): 555-P.
    13. Solař S. Možnosti inzulinové léčby diabetu typu 2 bazálním analogem detemir. Interní Med. 2007; 9 (7-8): 352-354.
    14. Standard of Medical Care in Diabetes, ADA, Diabetes Care, 2004; 27 (suppl 1): S15-S31.
    15. Svačina Š, Haluzík M. Role dlouhodobých inzulinových analog v terapii diabetu. Remedia 2007; 2: 153-157.
    16. Škrha J. Inzulinová analoga. Remedia 2006; 16: 164-169.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.